Glenmark Pharma, in partnership with Canada-based SaNOtize, has launched a nitric oxide nasal spray called FabiSpray in India for treating COVID-19 in adult patients who have high risk of progression of disease. The spray, used in the upper airways, reduced viral load of 94% in 24 hours and 99% in 48 hours during Phase 3 trial in India, Glenmark said.